MX2018011975A - Terapia de combinacion para tratamiento de leucemia mieloide aguda. - Google Patents
Terapia de combinacion para tratamiento de leucemia mieloide aguda.Info
- Publication number
- MX2018011975A MX2018011975A MX2018011975A MX2018011975A MX2018011975A MX 2018011975 A MX2018011975 A MX 2018011975A MX 2018011975 A MX2018011975 A MX 2018011975A MX 2018011975 A MX2018011975 A MX 2018011975A MX 2018011975 A MX2018011975 A MX 2018011975A
- Authority
- MX
- Mexico
- Prior art keywords
- myeloid leukemia
- acute myeloid
- treatment
- combination therapy
- amino
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title abstract 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 abstract 1
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662314700P | 2016-03-29 | 2016-03-29 | |
| US201662368343P | 2016-07-29 | 2016-07-29 | |
| PCT/JP2017/012293 WO2017170348A1 (en) | 2016-03-29 | 2017-03-27 | Combination therapy for the treatment of acute myeloid leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018011975A true MX2018011975A (es) | 2019-01-15 |
Family
ID=59965623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011975A MX2018011975A (es) | 2016-03-29 | 2017-03-27 | Terapia de combinacion para tratamiento de leucemia mieloide aguda. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190117649A1 (enExample) |
| EP (1) | EP3436014A4 (enExample) |
| JP (1) | JP2019512495A (enExample) |
| KR (1) | KR20180124055A (enExample) |
| CN (1) | CN108883109A (enExample) |
| BR (1) | BR112018069111A2 (enExample) |
| CA (1) | CA3018155A1 (enExample) |
| MX (1) | MX2018011975A (enExample) |
| RU (1) | RU2018134167A (enExample) |
| WO (1) | WO2017170348A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| EP3928780A4 (en) * | 2019-02-22 | 2022-12-07 | Hanmi Pharm. Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING A FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA |
| BR112021016522A2 (pt) * | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| KR20200102948A (ko) | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
| PL3949952T3 (pl) * | 2019-04-03 | 2024-10-14 | Astellas Pharma Inc. | Kompozycja farmaceutyczna |
| EP3991733A4 (en) | 2019-06-27 | 2023-07-05 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents |
| MX2022004555A (es) * | 2019-10-14 | 2022-07-21 | Astrazeneca Ab | Terapia de combinacion para tratar una neoplasia maligna hematologica. |
| CN114828842A (zh) * | 2019-10-21 | 2022-07-29 | 理森制药股份公司 | 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物 |
| KR20230056331A (ko) * | 2021-10-20 | 2023-04-27 | 한미약품 주식회사 | 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합 |
| WO2023129667A1 (en) | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| KR102559124B1 (ko) | 2022-08-25 | 2023-07-26 | 주식회사 엔젠바이오 | Flt3 유전자 증폭용 조성물 및 이의 용도 |
-
2017
- 2017-03-27 EP EP17774885.2A patent/EP3436014A4/en not_active Withdrawn
- 2017-03-27 WO PCT/JP2017/012293 patent/WO2017170348A1/en not_active Ceased
- 2017-03-27 CN CN201780021735.4A patent/CN108883109A/zh active Pending
- 2017-03-27 JP JP2018548236A patent/JP2019512495A/ja active Pending
- 2017-03-27 US US16/089,603 patent/US20190117649A1/en not_active Abandoned
- 2017-03-27 RU RU2018134167A patent/RU2018134167A/ru not_active Application Discontinuation
- 2017-03-27 MX MX2018011975A patent/MX2018011975A/es unknown
- 2017-03-27 CA CA3018155A patent/CA3018155A1/en not_active Abandoned
- 2017-03-27 KR KR1020187028124A patent/KR20180124055A/ko not_active Withdrawn
- 2017-03-27 BR BR112018069111-9A patent/BR112018069111A2/pt not_active Application Discontinuation
-
2020
- 2020-07-30 US US16/943,379 patent/US20200360372A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018069111A2 (pt) | 2019-03-19 |
| CN108883109A (zh) | 2018-11-23 |
| RU2018134167A3 (enExample) | 2020-06-30 |
| US20200360372A1 (en) | 2020-11-19 |
| JP2019512495A (ja) | 2019-05-16 |
| RU2018134167A (ru) | 2020-04-29 |
| EP3436014A4 (en) | 2019-11-27 |
| US20190117649A1 (en) | 2019-04-25 |
| EP3436014A1 (en) | 2019-02-06 |
| KR20180124055A (ko) | 2018-11-20 |
| WO2017170348A1 (en) | 2017-10-05 |
| CA3018155A1 (en) | 2017-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| PH12019502345A1 (en) | Methods of treatment using a jak inhibitor compoud | |
| PH12019500775A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| BR112018069111A2 (pt) | terapia de combinação para o tratamento de leucemia mieloide aguda | |
| PH12018500121A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| PH12017502107A1 (en) | Triazole agonists of the apj receptor | |
| PH12019502138A1 (en) | Compounds and compositions for treating hematological disorders | |
| MX2022005290A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| MX2021004598A (es) | Inhibidores selectivos de rgmc y el uso de los mismos. | |
| PH12018501084B1 (en) | Heterocyclic compounds as immunomodulators | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| EA033284B1 (ru) | ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА | |
| PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
| MX382927B (es) | Compuestos de benzolactama como inhibidores de la proteína cinasa. | |
| WO2017123568A3 (en) | Methods for the treatment of myeloid derived suppressor cells related disorders | |
| MY203583A (en) | Solubilized apyrases, methods and use | |
| MX2019015280A (es) | Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias. | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
| MX2018011283A (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer. | |
| WO2018211323A8 (en) | Heterocyclic compounds for the treatment of disease | |
| NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders |